RUN heads into mid-July with a rare and uncomfortable alignment: shorts at a multi-month high, options traders tilting bullish, and a cluster of executives selling into every bounce.
The insider story is the sharpest signal this week. On July 6 alone, five executives sold shares — including CEO Mary Grace Powell (23,985 shares, ~$316K) and President Paul Dickson (15,613 shares, ~$206K). CFO Danny Abajian also sold, as did the Chief Accounting Officer and HR Director. Co-founder and Co-Executive Chairman Lynn Jurich had already sold 50,000 shares on July 1 at $13.61, following identical 50,000-share sales on June 1 and May 1. That is three consecutive monthly tranches from the founder at progressively lower prices, netting roughly $2.1 million in aggregate. The 90-day net insider figure is technically positive at 235,306 shares, but that headline masks what has been an uninterrupted one-way flow of selling from the top of the house.
Short positioning adds weight to the picture. At 25.7% of free float — with 59.6 million shares short as of July 7, up around 1.2% over the past month — bearish conviction on RUN remains near its highest sustained level of the year. The ORTEX short score has edged up to 62.3, its highest reading in the available history, and the FINRA-reported 6.86 days-to-cover adds a mechanical drag to any rally attempt. Yet the borrow market tells a counterintuitive story: availability is running at roughly 511% of short interest — meaning there are more than five shares available to lend for every one already borrowed — and the cost to borrow is barely 0.49%, even after rising 16% over the past month. That is not a squeeze setup. Bears can still add at near-zero cost, and the lending pool shows no signs of stress.
Options positioning diverges sharply from the short book. The put/call ratio has dropped to 0.39, its lowest level in a year and more than one standard deviation below its 20-day average of 0.52. That means options traders are chasing calls, not buying puts — a notably bullish tilt for a stock down 9% on the week and 9% over the past month. Whether that reflects genuine upside conviction or tactical call-buying against a short position is unclear, but the contrast with the insider selling is stark.
The Street remains broadly constructive but has been steadily trimming targets. UBS cut its target to $20 from $23 on June 16 while keeping a Buy. Goldman Sachs, JPMorgan, TD Cowen, and Citigroup all lowered targets in April and May, yet all maintained positive ratings. The consensus mean target is $19, implying roughly 56% upside from the current $12.20 — but the gap between what analysts say and where the stock trades has been widening for months, not closing. One bear on the Street (GLJ Research, Sell, $4.63 target) stands well outside the consensus. Valuation gives some grounding: the stock trades at 12.8x trailing earnings and 0.85x book, and EV/EBITDA has compressed to 26.7x, down about 1.2 turns over the past month. The 90-day EPS momentum factor scores at the 100th percentile — but the 12-month forward EPS growth rank sits at just the 2nd percentile, and the short score ranks in the 7th percentile of its universe. The bull case rests on the 225% year-over-year surge in net value creation and the revised $1.0–$1.3 billion guidance range; the bear case centres on Q2 cash generation that came in at $27 million against guidance of $50–$60 million. Peers ARRY and SHLS both fell roughly 5-9% on the day and week, suggesting sector-wide pressure rather than stock-specific weakness — though EOSE has fared considerably worse, down 22% on the week.
The next identifiable catalyst is the July 2026 anniversary of recent clean energy legislation that management has flagged as a volume-securing milestone. Whether cash generation closes the gap with guidance by then — and whether the founder's monthly selling programme continues in August — will define how the short-versus-bull debate develops from here.
See the live data behind this article on ORTEX.
Open RUN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
